Pellitorine 是一种具有多种生物活性的天然酰胺类化合物,它可竞争性地拮抗 Capsaicin (MS-R45786) 对 TRPV1 的激活从而减少疼痛信号传导,通过上调 BDNF-ERK1/2-CREB 和 Nrf2-HO-1 通路改善认知功能障碍,通过抑制高迁移率组蛋白 B1 (HMGB1) 的释放和 RAGE/TLR4 的表达发挥抗炎和抗脓毒症作用,通过延长凝血时间以及抑制凝血因子和凝血酶的活性发挥抗血栓作用,通过上调 GPX4 和 DHODH 等蛋白抑制脂质过氧化、抵抗铁死亡 (ferroptosis),并可通过抑制 V 型 H⁺-ATP 酶 (V-type H⁺-ATPase) 和水通道蛋白 4 (AaAQP4) 杀灭埃及伊蚊幼虫,此外还具有抗癌活性 (如白血病、乳腺癌) 和抑菌活性。
产品编号: MS-J38724 纯度: 98.30% CAS No.: 18836-52-7 分子式: C14H25NO 分子量: 223.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Pellitorine 是一种具有多种生物活性的天然酰胺类化合物,它可竞争性地拮抗 Capsaicin (MS-R45786) 对 TRPV1 的激活从而减少疼痛信号传导,通过上调 BDNF-ERK1/2-CREB 和 Nrf2-HO-1 通路改善认知功能障碍,通过抑制高迁移率组蛋白 B1 (HMGB1) 的释放和 RAGE/TLR4 的表达发挥抗炎和抗脓毒症作用,通过延长凝血时间以及抑制凝血因子和凝血酶的活性发挥抗血栓作用,通过上调 GPX4 和 DHODH 等蛋白抑制脂质过氧化、抵抗铁死亡 (ferroptosis),并可通过抑制 V 型 H⁺-ATP 酶 (V-type H⁺-ATPase) 和水通道蛋白 4 (AaAQP4) 杀灭埃及伊蚊幼虫,此外还具有抗癌活性 (如白血病、乳腺癌) 和抑菌活性。

生物实验数据

生物活性 Pellitorine is a natural amide compound with multiple biological activities that competitively antagonizes Capsaicin (MS-R45786)-induced activation of TRPV1 to reduce pain signal transduction, improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways, exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group box 1 (HMGB1) and the expression of RAGE/TLR4, exerts antithrombotic effects by prolonging coagulation time and inhibiting the activities of coagulation factors and thrombin, inhibits lipid peroxidation and confers resistance to ferroptosis by upregulating proteins such as GPX4 and DHODH, kills Aedes aegypti larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4), and also possesses anticancer activity (e.g., leukemia, breast cancer) and antibacterial activity.
IC50 & Target

GPX4

 

ERK1

 

ERK2

 

TLR4

 

NF-κB

 

HO-1

 

体外研究
(In Vitro)

Pellitorine 对 HL60 和 MCF-7 具有细胞毒性,IC50 值分别为 13.0 µg/mL 和 1.8 µg/mL。
Pellitorine (0.01-1 mg/mL) 可阻断辣椒素诱导的 Ca2+ 摄取,在 HaCaT 细胞中的 IC50 为 154 µg/mL (0.69 mM/L)。
Pellitorine (0.1 nM-100 µM) 可显著延长部分凝血活酶时间 (aPTT) 和凝血酶原时间 (PT),并抑制正常人血浆中细胞内凝血酶和活化因子 X (FXa) 的活性。
Pellitorine (0-20 µM) 在人脐静脉内皮细胞中抑制 TNF-α 诱导的凝血酶和 FXa 的产生,下调 PAI-1 的分泌,降低 PAI-1/t-PA 比率,从而改善纤维蛋白溶解平衡。
Pellitorine (0-20 μM,6-30 h) 可抑制 LPS (MS-X54539) 诱导的屏障破坏、细胞粘附分子 (CAM) 的表达以及单核细胞粘附/跨内皮迁移至人内皮细胞。
Pellitorine (0-20 μM,7-22 h) 可抑制 LPS 刺激的人脐静脉内皮细胞产生 TNF-α 和 IL-6,或激活 NF-κB 和细胞外调节激酶 (ERK) 1/2。
Pellitorine 对枯草芽孢杆菌、球形芽孢杆菌、金黄色葡萄球菌、产气克雷伯菌和紫罗蓝色杆菌具有抗菌活性,MIC 值分别为 28、56、56、56 和 56 μM。

Cell Migration Assay

Cell Line: Monocytes through HUVEC monolayers
Concentration: 0, 3, 5, 10, 20 μM
Incubation Time: 6 h
Result: Inhibited the migration of monocytes across the endothelium.

ELISA Assay

Cell Line: HUVECs
Concentration: 0, 3, 5, 10, 20 μM
Incubation Time: Incubated for 6 h followed by LPS for 3 h (TLR4 and p-p38), 16 h (VCAM-1, ICAM-1, TNF-α and IL-6) or 24 h (E-Selectin)
Result: Inhibited expression of TLR4 and p-p38 level.
Decreased VCAM-1, ICAM-1 and E-selectin.
Decreased TNF-α and IL-6.
Inhibited phosphorylation of ERK1/2 and NF-κB expression.

RT-PCR

Cell Line: Monocytes through HUVEC monolayers
Concentration: 0, 3, 5, 10, 20 μM
Incubation Time: 6 h
Result: Significantly inhibited the upregulation of TLR4 induced by LPS.
Decreased VCAM-1, ICAM-1 and E-selectin mRNA.

Immunofluorescence

Cell Line: HUVECs
Concentration: 0, 3, 5, 10, 20 μM
Incubation Time: Incubated for 6 h followed by LPS for 1 h
Result: Reduced the nuclear translocation of NF-κB p65.
体内研究
(In Vivo)

Pellitorine (3.75 mM,含 100 µM Capsaicin,滴眼,单剂量) 可抑制小鼠对刺激性香草酸类物质引起的疼痛防御运动。
Pellitorine (2.21-5 mg/L,悬浮于含 Triton X-100 的蒸馏水中,将埃及伊蚊放入装有测试溶液的纸杯中) 主要攻击埃及伊蚊的中肠上皮和肛鳃,导致幼虫渗透压崩溃,随后死亡。
Pellitorine (0.1-0.6 mg/kg,腹腔注射,每日一次,共 21 天) 可通过抑制神经炎症和铁死亡来预防慢性束缚应激 (CRS) 诱发小鼠的认知缺陷。
Pellitorine (4.5-9 μg/mouse,静脉注射,单剂量) 显著延长小鼠尾部出血时间。
Pellitorine (9 μg/mouse,静脉注射,单剂量或双剂量) 可预防小鼠或降低 LPS 诱发的致死性内毒血症模型中小鼠的死亡率。

Animal Model: Eye wipe test established in BALB/c mice
Dosage: 3.75 mM applied together with 100 µM Capsaicin
Administration: Eye drops, single dose
Result: Significantly decreased the frequency of vanilloid-evoked defending movements.
Did not change significantly following either a 1 h or 15 min pretreatment with 3.75mM or 4.5 mM alone.
Animal Model: Insecticide test established in insecticide-susceptible Ae. Aegypti
Dosage: 2.21 and 5 mg/L, suspended in distilled water with Triton X-100 (20 ml/L)
Administration: Put Ae. Aegypti into paper cups containing the test solution
Result: Caused the epithelial cells of the gastric caeca to swell, disintegrate, and the cell nuclei to fragment.
Dissolved the electron-dense substances in the epithelial cells and leaves the residual peritubular membrane.
Damaged the anal-gill structure, resulting in neuronal damage.
Inhibited AaAQP4 expression levels and disturbed the Na+, Cl-, and K+ co-transport system mainly.
Caused the histopathological alterations and inhibition of gene expression of V-type H+-ATPase and aquaporin protein in the anal gills.
Animal Model: CRS model established in seven-week-old male C57BL/6 J mice
Dosage: 0.1 and 0.6 mg/kg
Administration: Intraperitoneally injection (i.p.), once daily for 21 days
Result: Significantly reduced the resting time of CRS mice in tails suspension test (TST).
Improved spatial memory of mice in novel object recognition test (NOR) and morris water maze (MWM).
Suppressed ferroptosis-associated signaling pathways and neuroinflammation.
Upregulated the expressions of GPX4, DHODH and FSP1.
Prevented neuronal loss, preserved the expression of neuroprotective molecules such as BDNF, Nrf2, HO-1, phosphorylated-CREB, and phosphorylated-ERK1/2.
Reduced the protein levels of inflammation-related markers including NLRP3, HMGB1, and NF-κB.
Reduced the number of activated microglia, as indicated by decreased Iba-1+, TREM2+, CD86+, and CX3CR1+ cell populations in the hippocampus.
Did not exhibit neurotoxicity in healthy mice.
Animal Model: Bleeding time test established in ICR mice
Dosage: 4.5 and 9 μg/mouse
Administration: Intravenous administration (i.v.), single dose
Result: Prolonged tail bleeding times from 41.6 s to 57.6 s and 71.8 s, respectively.
Animal Model: LPS-induced lethal endotoxemia model established in male C57BL/6 mice
Dosage: 9 μg/mouse
Administration: Intravenous administration (i.v.), two times at 12 h and 50 h after LPS injection or single dose at 12 h before LPS injection
Result: Prevented LPS-induced lethal endotoxemia.
Resulted in an increase in the survival rate from 0 to 30% by Kaplan-Meier survival analysis.
Suppressed LPS-induced hyperpermeability and leukocyte migration.
性状 固体
颜色 White to off-white

化学信息

分子量 223.35
分子式 C14H25NO
CAS No. 18836-52-7

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (223.86 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.4773 mL22.3864 mL44.7728 mL111.9319 mL
5 mM0.8955 mL4.4773 mL8.9546 mL22.3864 mL
10 mM0.4477 mL2.2386 mL4.4773 mL11.1932 mL
15 mM0.2985 mL1.4924 mL2.9849 mL7.4621 mL
20 mM0.2239 mL1.1193 mL2.2386 mL5.5966 mL
25 mM0.1791 mL0.8955 mL1.7909 mL4.4773 mL
30 mM0.1492 mL0.7462 mL1.4924 mL3.7311 mL
40 mM0.1119 mL0.5597 mL1.1193 mL2.7983 mL
50 mM0.0895 mL0.4477 mL0.8955 mL2.2386 mL
60 mM0.0746 mL0.3731 mL0.7462 mL1.8655 mL
80 mM0.0560 mL0.2798 mL0.5597 mL1.3991 mL
100 mM0.0448 mL0.2239 mL0.4477 mL1.1193 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Pellitorine 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础